Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $13.33 Average PT from Brokerages

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target […]